Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses

Astellas Pharma will highlight new data that enhances continued understanding of the science of geographic atrophy (GA), and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 4-8, Salt Lake City, Utah, and Retina World Congress (RWC), May 8-11, Fort Lauderdale, Florida.
 
The data comprises nine abstracts, including two oral presentations, featuring analyses on biomarkers, patient experience, mechanism of disease and other insights from the GATHER Phase 3 studies of Izervay for the treatment of GA secondary to age-related macular degeneration (AMD).
 
“Recognizing the early indicators and disease pathways of geographic atrophy are critical to helping patients preserve their existing vision for longer. We look forward to engaging with the retina community at ARVO and RWC to discuss the latest scientific insights in early diagnosis and effective management of GA,” said Marci English, senior vice president of biopharma and ophthalmology development at Astellas Pharma.
 
Research highlights include:

• An oral presentation on the structure-function relationship between baseline central subfield ellipsoid zone (EZ) integrity and visual acuity at baseline and future vision loss
• An oral presentation on baseline EZ integrity features linked to GA progression in eyes with differential shifts in GA growth rate
• Multiple posters evaluating imaging data from the GATHER1 and GATHER2 studies, which link structure and function in GA
• Two preclinical posters with structural insights refining the mechanism of action, as well as pharmacokinetics and pharmacodynamics, of avacincaptad pegol (ACP)
• Data from qualitative studies assessing the experience of patients with GA in the United States, Spain, Germany and France, including the impact of disease symptoms on health-related quality of life (HRQoL) and coping mechanisms used to manage symptoms of GA

Astellas Presentations at 2025 ARVO Annual Meeting

• Association of baseline central subfield ellipsoid zone integrity with baseline visual acuity and future vision loss in the GATHER clinical trials
  • Presentation Number: 4594
  • Date: May 7, 2025; 3:30-3:45 PM MT
• Understanding the experience of people living with geographic atrophy in the United States, Spain, France and Germany
  • Posterboard Number: 807 - B0259
  • Date: May 4, 2024; 1:00-2:45 PM MT
• Structural insights into the mechanism of inhabitation of C5 activation by avacincaptad pegol, an aptamer approved for the treatment of geographic atrophy secondary to age-related macular degermation
  • Posterboard Number: 2522 - B0235
  • Date: May 5, 2025; 3:00 – 4:45 PM MT
• Nonclinical pharmacology and pharmacokinetic properties of avacincaptad pegol, an aptamer against C5 approved for the treatment of geographic atrophy secondary to age-related macular degeneration
  • Posterboard Number: 2539 - B0252
  • Date: May 5, 2025; 3:00 – 4:45 PM MT
• iRORA phenotype characterization using fundus autofluorescence: GATHER2 post-hoc analysis for geographic atrophy secondary to AMD
  • Posterboard Number: 3468 - B0031
  • Date: May 6, 2025; 1:15 – 3:00 PM MT
• Association of ellipsoid zone integrity features with diffuse trickling fundus autofluorescence patterns in the GATHER1/GATHER2 clinical trials
  • Posterboard Number: 3512 - B0075
  • Date: May 6, 2025; 1:15 – 3:00 PM MT
• Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with geographic atrophy in the GATHER1 and GATHER2 clinical trials
  • Posterboard Number: 4123 - A0121
  • Date: May 7, 2025; 10:15 AM – 12:00 PM MT
• Ellipsoid zone integrity features linked to differential shifts in geographic atrophy growth rate in the GATHER1 and GATHER2 clinical trials
  • Posterboard Number: 4220 - A0218
  • Date: May 7, 2025; 10:15 AM – 12:00 PM MT

Astellas Presentations at RWC 2025 Meeting

• Ellipsoid zone integrity features linked to differential shifts in geographic atrophy growth rate in the GATHER1 and GATHER2 clinical trials
  • Date: May 9, 2025; 2:38 – 2:43 pm ET

*avacincaptad pegol intravitreal solution (ACP) is approved for use as IZERVAY™ only in the U.S.